Methods of treating chronic heart failure (CHF) by increasing the high energy phosphate concentrations available to heart muscle by administering a xanthine oxidase inhibitor to a patient having CHF are provided. As a result of such therapy, contractility of the heart is improved.
Christopher Lademacher - Evanston IL, US Lin Zhao - Vernon Hills IL, US Richard Johnson - Gainesville FL, US
International Classification:
A61K 31/53 A61K 31/426 A61K 31/4196 A61K 31/415
US Classification:
514246000, 514365000, 514383000, 514406000
Abstract:
The present invention relates to methods of treating subjects suffering from pre-hypertension or hypertension by administering to a subject in need of treatment thereof a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.
Methods For Delaying The Progression Of At Least One Of Cardiac Hypertrophy, Cardiac Remodeling Or Left Ventricular Function Or The Onset Of Heart Failure In Subjects In Need Of Treatment Thereof
The present invention relates to methods for reducing the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular dysfunction following a cardiac insult in a subject in need of treatment thereof. Moreover, the present invention also relates to methods of delaying the onset of heart failure symptoms or reducing the incidence of cardiovascular events following a cardiac insult in a subject in need of treatment thereof.
Methods of treating chronic heart failure (CHF) by increasing the high energy phosphate concentrations available to heart muscle by administering a xanthine oxidase inhibitor to a patient having CHF are provided. As a result of such therapy, contractility of the heart is improved.
- Deerfield IL, US Lin Zhao - Vernon Hills IL, US Richard Johnson - Gainesville FL, US
International Classification:
C07D 277/56 A61K 45/06 A61K 31/426
US Classification:
514365
Abstract:
The present invention relates to methods of treating subjects suffering from pre-hypertension or hypertension by administering to a subject in need of treatment thereof a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.